Antimicrobial resistance (AMR) is one of the most serious global public health threats in this
century. The first World Health Organization (WHO) Global report on surveillance of AMR …

The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and
difficult challenges facing global TB control. Patients who are infected with strains resistant …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …

Objectives To describe the grading of recommendations assessment, development and
evaluation (GRADE) interactive evidence to decision (EtD) frameworks for tests and test …

Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …

Tuberculosis (TB) is a major public health concern worldwide: despite a regular, although
slow, decline in incidence over the last decade, as many as 8.6 million new cases and 1.3 …

Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Tuberculosis is an airborne infectious disease treated with combination therapeutic
regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining …

Bedaquiline, a new antituberculosis drug, has already been used in> 50 countries. The
emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this …

Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …